Lesson 4: Stem cells, mitosis and differentiation
Evaluate an iPS cell therapy for macular degeneration
SkillStem cells and potency
Worked example
In age-related macular degeneration, a layer of cells behind the retina (the retinal pigment epithelium) dies and central vision is lost. In 2014 researchers in Japan took skin cells from a patient, reprogrammed them into iPS cells, grew them into a sheet of retinal pigment epithelium and transplanted it into her eye. A year later the sheet was still in place, there was no sign of rejection or tumours, and her vision had stopped getting worse, though it had not improved.
Evaluate the use of iPS cells for this treatment, considering its safety, ethics and efficacy.
Step 1: Explain the biology
iPS cells are specialised cells reprogrammed to be pluripotent, so they can be differentiated into the required cell type, here retinal pigment epithelium.
Step 2: Safety
For: the cells came from the patient, so they are genetically identical to her and were not rejected; no immunosuppressive drugs were needed. No tumours were seen after a year.
Against: one patient followed for one year is far too little to rule out tumours from any cells that stayed pluripotent, or mutations introduced while the cells were grown.
Step 3: Ethics
For: no embryo was destroyed, avoiding the main objection to embryonic stem cells. The patient could give informed consent to use her own cells.
Against: an experimental treatment carries unknown risks; making cells for each patient is very expensive, raising questions of fair access.
Step 4: Efficacy
The sheet survived and the disease stopped progressing, which is encouraging. But vision did not improve, and a result in a single patient cannot show whether the treatment works in general; controlled trials with many patients are needed.
Step 5: Make a judgement
The treatment is promising, and safer and more ethically acceptable than using embryonic stem cells, but it is not yet proven safe or effective. It should continue in larger clinical trials before it is offered as a standard treatment.
"Evaluate" requires a judgement supported by the points above, not just a list.
Answer
Promising: patient-derived iPS cells avoided rejection and the destruction of embryos, and the sheet survived without tumours. But one patient over one year cannot establish long-term safety (tumour risk) or efficacy (vision only stabilised), and the cost is high, so larger trials are needed before routine use.
Try a similar one
A fresh question of the same kind, checked as you answer, with hints and a full solution.
Method
Explain the relevant biology briefly (what iPS cells are).
Give points for and against under safety, ethics and efficacy, each specific to the case.
Comment on the strength of the evidence (sample size, follow-up time).
Finish with a reasoned judgement.
Watch out for
Listing advantages and disadvantages without a final judgement.
Treating one successful case as proof that the treatment works.